Notis McConarty Edward Has $1.67 Million Position in Merck & Co., Inc. (NYSE:MRK)

Notis McConarty Edward reduced its position in shares of Merck & Co., Inc. (NYSE:MRK) by 1.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,800 shares of the company’s stock after selling 350 shares during the period. Notis McConarty Edward’s holdings in Merck & Co., Inc. were worth $1,666,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Schaper Benz & Wise Investment Counsel Inc. WI raised its holdings in Merck & Co., Inc. by 1.9% during the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 68,131 shares of the company’s stock worth $5,735,000 after acquiring an additional 1,257 shares in the last quarter. Montag A & Associates Inc. raised its holdings in Merck & Co., Inc. by 5.7% during the third quarter. Montag A & Associates Inc. now owns 217,886 shares of the company’s stock worth $18,342,000 after acquiring an additional 11,800 shares in the last quarter. First Trust Advisors LP raised its holdings in Merck & Co., Inc. by 2.4% during the third quarter. First Trust Advisors LP now owns 1,421,805 shares of the company’s stock worth $119,688,000 after acquiring an additional 33,165 shares in the last quarter. Unigestion Holding SA raised its holdings in Merck & Co., Inc. by 8.5% during the third quarter. Unigestion Holding SA now owns 162,591 shares of the company’s stock worth $13,686,000 after acquiring an additional 12,679 shares in the last quarter. Finally, Haverford Trust Co. raised its holdings in Merck & Co., Inc. by 1.5% during the third quarter. Haverford Trust Co. now owns 536,852 shares of the company’s stock worth $45,192,000 after acquiring an additional 8,045 shares in the last quarter. 74.95% of the stock is owned by institutional investors.

Several research firms have issued reports on MRK. Leerink Swann began coverage on Merck & Co., Inc. in a research note on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price objective on the stock. Societe Generale set a $105.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Svb Leerink began coverage on Merck & Co., Inc. in a research note on Friday, August 16th. They issued an “outperform” rating and a $103.00 price objective on the stock. ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Bank of America began coverage on Merck & Co., Inc. in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $95.13.

NYSE:MRK traded up $0.71 on Friday, hitting $83.59. The company’s stock had a trading volume of 6,348,296 shares, compared to its average volume of 10,105,755. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The stock has a fifty day moving average of $84.01 and a two-hundred day moving average of $82.77. The firm has a market capitalization of $212.31 billion, a P/E ratio of 19.26, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.27. The firm had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.19 earnings per share. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: What is Green Investing?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.